Melinta Therapeutics Announces Pricing of Public Offering of Common Stock

NEW HAVEN, Conn. , May 23, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the pricing of an underwritten public offering of 22,000,000

READ FULL TEXT

Leave a Reply

Your email address will not be published.